The news yesterday from Amgen that panitumumab (Vectibix) failed in Head and Neck cancer got me thinking. Why did it fail where cetuximab (Erbitux) succeeded? They're both monoclonal antibodies to EGFR, so that makes it rather interesting.
« Bio-Betters = Lower Risk? | Main | Allozyne Licenses Sigma-Aldrich Cycloaddition Technology »
08/12/2010
Why do some cancer drugs work and others don't?
| | |
TrackBack
TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a0120a77f675b970b013486291305970c
Listed below are links to weblogs that reference Why do some cancer drugs work and others don't?:
The comments to this entry are closed.
Recent Posts
- Pharma R&D Spending vs Other Industries
- Innovation as Illustrated by Beer
- Global Biosimilar Market Report 2013
- The Outcomes Era
- Latest Myriad Case Commentary
- Pharma Need for Adapting to Change
- US Drug Market Contracts for First Time - EVER!
- R&D Spending may not be ALL Bad
- Myriad BRCA Test Cost is In-Line
- Pharma vs Society - Let's Get Ready to Stuuuummmbbble!
Search
Archives
- May 19, 2013 - May 25, 2013
- May 12, 2013 - May 18, 2013
- May 5, 2013 - May 11, 2013
- April 28, 2013 - May 4, 2013
- April 21, 2013 - April 27, 2013
- April 14, 2013 - April 20, 2013
- April 7, 2013 - April 13, 2013
- March 31, 2013 - April 6, 2013
- March 24, 2013 - March 30, 2013
- March 17, 2013 - March 23, 2013
Categories
- AIDs
- Animal Health
- Antibody Drug Conjugates
- Brazil News
- Business Model
- Cell Engineering
- China news
- Clinical Results
- CNS Therapies
- Conservative Curmudgeon Palaver
- Current Events
- Development Funding & Investment
- Drug Development
- Economics
- Ethics
- Facility News
- FDA & EU Approvals
- Gene Therapy
- Generics & Biosimilars
- Government Policy
- Healthcare Reform
- India News
- Innovation
- Korea News
- Liberal Altruisim
- Manufacturing Challenges
- Market Data & Facts & Research
- Market Rumors
- Mergers & Acquisitions
- Oncology
- OpEx and Lean
- Orphan, Neglected & Rare Diseases
- Outsourcing
- Patents & Legal
- Personalized Medicine
- Process Development
- Product Licensing/Acquisition
- Product Recalls/Warning Letters
- Quality Management Systems
- R&D Changes & Trends
- Random Fun Stuff
- Raw Material Detectives
- Raw Material Testing
- Regenerative Medicine & Stem Cells
- Regulatory Affairs & Policy
- Reimbursement & 3rd Party Payers
- Risk Mitigation
- RNAi therapeutics
- Russia News
- Science & Technology
- Supply Chain Management
- Trade Policy
- Trade Shows, Seminars, & Webinars
- Translational Medicine
- Vaccines & Virus
- Venture Capital
- Virtual Biotech's
- Weblogs & Websites
- Whitepapers
Comments